AstraZeneca's Brilique first to be assessed under Germany's AMNOG, getting positive view
The German reimbursement body, the Federal Joint Committee (G-BA), has published the Institute for Quality and Efficiency in Healthcare (IQWiG) preliminary assessment report regarding the medical benefit of Anglo-Swedish drug major AstraZeneca’s (LSE: AZN) clot buster Brilique (ticagrelor; also sold as Brilinta).
The company said it is pleased with this preliminary assessment as it seeks to help ensure acute coronary syndromes (ACS) patients continue to have access to this innovative drug in Germany, Europe’s largest pharmaceutical market. Ticagrelor is forecast to generate peak sales of the order of $2.3 billion globally. Credit Suisse analysts put a net present value for Brilinta/Brilique of £1.17 per share of AstraZeneca, whose stock rose more than 0.8% in early London trading this morning to £28.38.
New system expected to save 2 billion euros
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze